Pharmaceuticals, Biotechnology and Life Sciences
Eli Lilly’s Taltz met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, testing Taltz versus TREMFYA (guselkumab) in people living with moderate to severe plaque psoriasis (PsO).
Eli lilly is encouraged by the results of the COAST-X trial, which support its belief that Taltz could become the first IL-17A antagonist to be approved in the U.S. for people with non-radiographic axSpA, said Christi Shaw, president, Lilly Bio-Medicines.
Eli Lilly said Tuesday that the U.S. Food and Drug Administration (FDA) has approved a label update for Taltz injection 80 mg/mL to…
TALTZ was recently approved by the U.S. Food and Drug Administration to treat adults with moderate-to-severe plaque psoriasis.